Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025
Myriad Genetics, Inc.
Myriad Genetics Inc (MYGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 4,069,526 | $36,096,696 | -7% | 0.02% |
| 2. | Glenview Capital Larry Robbins | 3,899,550 | $34,589,009 | -7% | 0.85% |
| 3. | D E Shaw D. E. Shaw | 2,522,618 | $22,375,622 | +39% | 0.02% |
| 4. | Camber Capital Management Stephen Dubois | 2,350,000 | $20,844,500 | -25% | 0.74% |
| 5. | Fisher Asset Management Ken Fisher | 1,075,215 | $9,537,156 | +19% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.62 | 15,000 | $249,336.00 | 66,790 | 2020-11-11 | Filing | |
| $25.60 | 5,860 | $149,997.83 | 54,150 | 2019-12-13 | Filing | |
| $23.46 | 1,750 | $41,055.70 | 2,050 | 2019-11-07 | Filing | |
| $23.46 | 5,250 | $123,167.10 | 64,353 | 2019-11-07 | Filing | |
| $18.57 | 400 | $7,429.20 | 42,524 | 2017-02-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.93 | 15,000 | $343,950.00 | 962,378 | 2024-10-11 | Filing | |
| $26.72 | 15,000 | $400,800.00 | 977,378 | 2024-09-11 | Filing | |
| $26.17 | 2,100 | $54,961.20 | 108,013 | 2024-09-11 | Filing | |
| $27.05 | 10,000 | $270,520.00 | 121,648 | 2024-09-09 | Filing | |
| $27.95 | 46,012 | $1,285,851.35 | 42,533 | 2024-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,458,176 | $137,114,021 | 0% | |
| 2. | 10,667,755 | $94,622,986 | 0% | |
| 3. | 5,268,790 | $46,734,167 | 0% | |
| 4. | 4,733,692 | $41,987,848 | 0.87% | |
| 5. | 4,592,264 | $40,733,383 | 0.01% |
News See All
Billionaire Larry Robbins' 10 Stock Picks with Huge Upside Potential
Larry Robbins is an American hedge fund manager and philanthropist who founded Glenview Capital Management in 2000. The firm manages capital for investors across a range of private investment funds.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript
Operator: Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.
Top 8 Trending AI News Updates Investors Should Not Miss
As AI takes over industries worldwide, the technology has begun replacing the redundant human workforce, as popular banks reveal plans to shrink headcount amid rapid AI adoption.
Billionaire Larry Robbins' Long-Term Stock Picks
Larry Robbins is an American hedge fund manager, philanthropist, and the founder, CEO, and portfolio manager of Glenview Capital, a leading New York-based investment firm.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Call Transcript
Matt Scalo: Thank you, Franz, and good afternoon, and welcome to the Myriad Genetics third quarter 2024 earnings call. During the call, we will review financial results we released today.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Myriad Genetics Second Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Myriad Genetics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript
Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $0.02. Myriad Genetics, Inc.